The prevalence of heart failure (HF) is 1%-2% among adult population in developed countries and 6-10% in the elderly groups. It is rising with an estimated 660,000 new cases each year [1] [2] [3] [4] [5] . In China, the HF prevalence increased to 29.1% from 16.9% 6 . The USA HF thirty-day mortality rate has decreased; however, the post-discharge mortality rate, re-admission, and admissions to nursing home facilities have increased. The economic burden of HF remains high [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [136] [137][138] .
INTRODUCTION
The prevalence of heart failure (HF) is 1%-2% among adult population in developed countries and 6-10% in the elderly groups. It is rising with an estimated 660,000 new cases each year [1] [2] [3] [4] [5] . In China, the HF prevalence increased to 29.1% from 16.9% 6 . The USA HF thirty-day mortality rate has decreased; however, the post-discharge mortality rate, re-admission, and admissions to nursing home facilities have increased. The economic burden of HF remains high [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [136] [137] [138] .
A 2004 review has shown that HF disease management programs can reduce HF hospitalizations by 27%. However, HF hospitalization costs in the USA have increased by more than 175% during the last 25 years [18] [19] [20] . Incomplete implementation of trial methodology, inadequate patient education, absence of trained staff for follow-up monitoring, non-access to specialized HF clinics, application of complex adaptive systems framework, or disease management programs are possible reasons for the continued high burden of HF [21] [22] [23] [24] [25] [26] [27] [28] [29] . In a systematic review of chronic HF guidelines from Europe, 56% were consensus-based and 28%
were evidenced-based advisories [30] [31] [32] [33] [34] [35] [36] . Furthermore, guidelines recommendations do not highlight the signifi cant contribution of BDT. The concern is the lack of a statement describing that the Class I-A recommended IDT is in fact an ADT to the BDT .
OBJECTIVES
To determine the survival and hospitalization event free rate in the BDT and IDT groups and to compute for the ADT survival and hospitalization event free rates. [38] [39] [40] [41] [42] [43] [44] [45] .
METHODOLOGY
Other chronic HF studies and guidelines were reviewed for comparison [46] [47] [91] [92] [93] [94] [95] [96] .
Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?
BDT refers to the background HF ('start') medications used as placebo in the trial. IDT refers to the experimental ('end') drug used in the trial and is the guidelines' suggested fi rst line HF drug therapy. The add-on HF drug therapy or ADT survival and hospitalization event free rate is the absolute value of the difference between the BDT and the IDT rates. The natural HF survival rate of 38% is assumed based on published literature for the time period 107 . In summary, the reviewed HF studies showed the following:
RESULTS
(1) The proportion of HF studies with BDT: 79% -100% (2) The Survival benefi t of BDT group: 46% -89% (3) The Survival benefi t of IDT group: 61% -92.8% (4) The Survival benefi t of ADT group: 0.4% -15%. 
DISCUSSION
The chronic HF trials referenced in the chronic HF guidelines listed the use of numerous HF medications which comprised BDT [45] [46] [47] [48] . The extent of the survival benefit of the BDT is 46% -89% and the IDT is 61 % -92.8% with a calculated ADT survival of 0.4 % -15 % 52, 64-65 . The extent of the HF hospitalization free event rates of the BDT is 47.1% -85.3% and the IDT drug therapy is 61.8% -90% with a calculated ADT hospitalization free event rate of 4.6% -14.7% 52, [64] [65] . Our review highlights a 6 times (89/15) survival rate in the BDT compared to the ADT and a 6 to 10 times (85.3/14.7 and 47.1/4.6) HF hospitalization-free event rate in the BDT compared to the ADT.
HF Survival and Hospitalization
Hospitalization marks a fundamental change in the natural history of HF. Three-fourths of all HF hospitalizations are due to symptom exacerbation with one-half of hospitalized HF patients experiencing readmissions within 6 months. Preventing HF hospitalization and re-hospitalization is important to improve patient outcomes and curb health care costs 67, 68 .
Avoidance of hospital admission can be equivalent to prolonging quality of life [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] .
Repeat HF hospitalization ranged from 22.7% in Latin America and 43.9% in North America 143-144 . Two-thirds of patients hospitalized for acute decompensated chronic heart failure have already survived a known history of heart failure. [145] [146] . In the OPTIMIZE-HF Registry, rates of re-hospitalization were 30% post discharge [173] [174] . In the EVEREST trial, 40% of post discharge deaths were from HF [173] [174] . A prior history of HF decompensation or hospitalization identifi es patients who are particularly at high risk of recurrent events [147] [148] . Is HF re-hospitalization associated with ADT with or without BDT?
Baseline HF Drug Therapy
Withdrawal effect: A meta-analysis of loop diuretics in HF found a statistically signifi cant survival benefi t on top of baseline HF therapy 74 . Studies have showed that ACEi or digoxin use lowered mortality (OR 0.24); reduced worsening HF (OR 0.07), and improved exercise capacity. (OR 0.72) [72] [73] [74] [75] . The PROVED and RADIANCE showed worsening HF occurred at 4.7% (digoxin, ACEi and diuretic therapy); 25% (ACEi and diuretic therapy); and 39% on diuretic alone (76-83) after withdrawal. Thus, the combination of digoxin, ACEi, and loop diuretic are relevant as BDT. Digoxin and loop diuretic withdrawal have adverse consequences. 175, 149 .
Diuretic effect: Doubling the dose of diuretics among symptomatic HF patients on beta blockers, ACEi or ARB, spironolactone, and digoxin, led to signifi cant loss of weight, improvement in symptoms, and an increase in 6-minute walk distance [150] [151] . Is this a cardio-renal effect?
Digoxin use and level: Recent opinions say that "not enough data supports the use of digoxin with current medications for chronic systolic heart failure like betablocker, spironolactone, and ACEI." Thereby, the use of digoxin has not been emphasized in chronic heart failure treatment" guidelines 152 . There is evidence to show the contrary.
One study showed a 34% lower rate of all cause hospital admission in patients assigned to digoxin. This fi nding highlights an early benefi cial effect of digoxin. 44% of patients enrolled in the DIG study used digoxin, those on digoxin maintained the treatment, while digoxin was stopped (without a washout period) among those assigned in the placebo 153 . Can this explain why the DIG study did not show all-cause mortality reduction since the placebo arm previously benefi ted from digoxin use?
Other studies have shown all-cause hospitalizations occurred in 5.4% vs 8.1% among chronic HF patients on Digoxin reduces hospitalizations and improves symptoms when dosed to achieve low serum concentrations of 0.5-0.9 ng/ml (HR 0.81; 0.71-0.92) 176 . Further, studies have showed that lower serum digoxin concentration (0.5-0.9 ng/mL) was associated with reduced all-cause mortality (HR 0.77; 0.67-0.89), cardiovascular mortality (HR 0.83; 0.71-0.97), and heart failure mortality (HR 0.63; 0.49-0.82) (162). Current guidelines do not sufficiently emphasize the need to achieve low serum digoxin concentrations [160] [161] . The DIG study is the only chronic HF study with serum digoxin level (SDL) determination.
Add on HF Drug Therapy
Total mortality or hospitalization, MI, and stroke did not differ between ARB and ACEi. Adverse effects resulted in increased withdrawals with combination ACEi and ARB 101 . Studies on BB therapy showed it improved survival, hospitalization, LV function, dyspnea, exercise tolerance time, NYHA FC, reduced death or readmission (OR=0.74), death or re-infarction (OR=0.77) or sudden death (OR=0. 80) 102,103,163,164 .
Short-term effects of BB withdrawal in acute decompensated heart failure have been reported 177 . BB withdrawal significantly increased risk of in-hospital mortality (RR 3.72;1.51 to 9.14), short-term mortality (RR 1.61;1.04 to 2.49), and combined short-term rehospitalization or death (RR1.59; 95% CI: 1.03 to 2.45). This data suggests BB should be continued in HF patients unless contraindicated 165 .
In CAD patients with heart failure and preserved systolic function, low-dose digoxin was significantly more effective than ivabradine 166. Digitalis showed an OR for mortality of 0.98 (0.89-1.09), hospitalization of 0.68 (0.61-0.75), and clinical HF deterioration of 0.31 (0.21-0.43). Digoxin has no effect on long-term mortality; however, it reduced hospitalization and improved clinical status of symptomatic HF patients 104, 105 .
The Extrapolation
In the 21 st century, the combination use of ACEI, ARB, BB, and aldosterone antagonist decreased hospitalizations and improved survival [112] [113] . However, baseline HF drug therapy with digoxin and diuretics is a relevant concern 66, 48, 114 .
If the recommended initial HF drug therapy survival rate is actually the add-on HF drug therapy recommended Class 1-A survival rate (computed as initial HF drug therapy survival rate MINUS the baseline HF drug therapy survival rate), then the computed add on HF drug therapy survival rate will be 0.4 % -15 %. Similarly, the computed add on HF drug therapy hospitalization free event rate will be 4.6 % -14.7 %.
The natural HF history survival in fi ve years prior to current evidenced-based effective therapy is assumed to be 38% 107 . Therefore, given the derived baseline HF drug therapy survival rate of 46 % to 89 % MINUS 38% assumed natural HF survival rate, the extrapolated baseline HF drug therapy survival rate is 8% to 51% which is higher than the add-on HF drug therapy Class 1-A recommendation survival rate of 0.4 % -15 %.
Economic Impact of HF treatment
"The implementation of evidence-based therapy for HF treatment is not only clinically effi cacious, but also economically attractive" 97 . To implement cost-effective strategies and contain the HF hospitalization epidemic, optimal identifi cation of high-risk individuals and various multi-marker risk prediction schemes have to be developed 98 . Indeed, digoxin use gave a cost saving of >50% of several higher-risk HF patient subgroups 99 . Thus, combination HF therapy is still related to cost and clinical benefi ts.
GUIDELINES ADHERENCE
In chronic HF cases and despite management by cardiologists, medical prescription differed substantially (> 50%) from guidelines' recommendations 167 . The percentage of patients taking β-blockers was 38%; the percentage taking angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) was 32% 168 . Target doses for ACEi or ARB and BB were low at 40.3% and 28.9%, respectively 169 . Furthermore, the Heart Failure Adherence and Retention Trial has determined that 37% did not adhere to HF evidence-based guidelines 170 . In the China Outpatient HF Study, patients received target dose of ACEI/ARB (17.92%), BB (17.92%), respectively 171 .The low guideline directed medical therapy, usually IDT adherence, highlights the relevance of BDT
LIMITATIONS
The HF studies reviewed were limited to references and our analysis depended on the published trial data cited in the AHA/ACC, HFSA, and the ESC chronic HF guidelines without uniform "chronic HF defi nitions" although "unstable HF state" was excluded 38, 39, [41] [42] [43] [44] [45] . A later guideline review classifi ed HF with typical HF symptoms, physical fi ndings and defi nitive EF levels 46 .
The specifi c value of BDT and ADT to HF natural disease progression are unclear and hard to quantify at present. Whether digoxin added cost savings and reduced mortality and hospitalization is also speculative at this time. Other issues may affect the HF natural survival history thereby reducing the extrapolated survival benefi ts attributed to the BDT such as the following: (i) the contribution of renal failure, respiratory disease, anemia, cognitive impairment, falls and urinary incontinence 118 ; (ii) the 'real world' acute HF exacerbations and re-admissions mortality of 8.2% that is independent of age, BP and creatinine levels 119, 120 ; (iii) the 9.6% mortality and 19.4% re-hospitalization for CV causes at 90 days of HF admission , (ix) the interactions between multiple drugs which affects acceptance and compliance 127 , and (x) family education at home to enhance patient self-care, boost dietary and treatment adherence 182 .
These undetermined and still unrecognized factors impact on the natural HF history and were not analyzed in this paper.
Whether digoxin added cost savings and reduced mortality and hospitalizations can translate into substantial changes in the survival benefi t attributable to baseline therapy is also speculative at this time.
CONCLUSION
The contribution of baseline HF drug therapy (BDT) is relevant in terms of the survival and hospitalization-free event rates compared to the HF class 1-A guidelines recommendations (IDT). Further, the proposed initial HF drug ('end') therapy (IDT) has possible synergistic effects to the baseline HF drug ('start') therapy (BDT) and is essentially the add on HF drug therapy (ADT) in our analysis. The polypharmacy HF treatment is a synergistic effect due to BDT and ADT. 
